MIRUM PHARMACEUTICALS INC (MIRM) Fundamental Analysis & Valuation

NASDAQ:MIRM • US6047491013

Current stock price

88.51 USD
-2.21 (-2.44%)
At close:
88.51 USD
0 (0%)
After Hours:

This MIRM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. MIRM Profitability Analysis

1.1 Basic Checks

  • MIRM had negative earnings in the past year.
  • In the past year MIRM had a positive cash flow from operations.
  • In the past 5 years MIRM always reported negative net income.
  • In multiple years MIRM reported negative operating cash flow during the last 5 years.
MIRM Yearly Net Income VS EBIT VS OCF VS FCFMIRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • MIRM has a Return On Assets of -2.77%. This is amongst the best in the industry. MIRM outperforms 87.14% of its industry peers.
  • MIRM's Return On Equity of -7.42% is amongst the best of the industry. MIRM outperforms 88.29% of its industry peers.
Industry RankSector Rank
ROA -2.77%
ROE -7.42%
ROIC N/A
ROA(3y)-13.72%
ROA(5y)-21.62%
ROE(3y)-37.37%
ROE(5y)-55.51%
ROIC(3y)N/A
ROIC(5y)N/A
MIRM Yearly ROA, ROE, ROICMIRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • MIRM has a Gross Margin of 80.77%. This is amongst the best in the industry. MIRM outperforms 84.84% of its industry peers.
  • In the last couple of years the Gross Margin of MIRM has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for MIRM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.28%
GM growth 5YN/A
MIRM Yearly Profit, Operating, Gross MarginsMIRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MIRM Health Analysis

2.1 Basic Checks

  • MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MIRM has been increased compared to 1 year ago.
  • The number of shares outstanding for MIRM has been increased compared to 5 years ago.
  • MIRM has a better debt/assets ratio than last year.
MIRM Yearly Shares OutstandingMIRM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
MIRM Yearly Total Debt VS Total AssetsMIRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 5.98 indicates that MIRM is not in any danger for bankruptcy at the moment.
  • MIRM has a Altman-Z score of 5.98. This is in the better half of the industry: MIRM outperforms 75.82% of its industry peers.
  • The Debt to FCF ratio of MIRM is 5.65, which is a neutral value as it means it would take MIRM, 5.65 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of MIRM (5.65) is better than 91.36% of its industry peers.
  • MIRM has a Debt/Equity ratio of 0.98. This is a neutral value indicating MIRM is somewhat dependend on debt financing.
  • MIRM's Debt to Equity ratio of 0.98 is on the low side compared to the rest of the industry. MIRM is outperformed by 75.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 5.65
Altman-Z 5.98
ROIC/WACCN/A
WACC8.71%
MIRM Yearly LT Debt VS Equity VS FCFMIRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • MIRM has a Current Ratio of 2.67. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.67, MIRM is doing worse than 68.52% of the companies in the same industry.
  • A Quick Ratio of 2.55 indicates that MIRM has no problem at all paying its short term obligations.
  • MIRM has a Quick ratio of 2.55. This is in the lower half of the industry: MIRM underperforms 67.56% of its industry peers.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.55
MIRM Yearly Current Assets VS Current LiabilitesMIRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. MIRM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 74.59% over the past year.
  • Looking at the last year, MIRM shows a very strong growth in Revenue. The Revenue has grown by 54.74%.
  • MIRM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 89.13% yearly.
EPS 1Y (TTM)74.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.59%
Revenue 1Y (TTM)54.74%
Revenue growth 3Y89.13%
Revenue growth 5YN/A
Sales Q2Q%49.81%

3.2 Future

  • MIRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 81.09% yearly.
  • Based on estimates for the next years, MIRM will show a very strong growth in Revenue. The Revenue will grow by 25.19% on average per year.
EPS Next Y-105.78%
EPS Next 2Y52.72%
EPS Next 3Y66.03%
EPS Next 5Y81.09%
Revenue Next Year25.28%
Revenue Next 2Y23.51%
Revenue Next 3Y24.06%
Revenue Next 5Y25.19%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MIRM Yearly Revenue VS EstimatesMIRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
MIRM Yearly EPS VS EstimatesMIRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. MIRM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MIRM. In the last year negative earnings were reported.
  • Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRM Price Earnings VS Forward Price EarningsMIRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

  • MIRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MIRM is cheaper than 88.68% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MIRM is valued cheaply inside the industry as 90.40% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 97.33
EV/EBITDA 2457.55
MIRM Per share dataMIRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • MIRM's earnings are expected to grow with 66.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.72%
EPS Next 3Y66.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MIRM Dividend Analysis

5.1 Amount

  • MIRM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MIRM Fundamentals: All Metrics, Ratios and Statistics

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (3/20/2026, 8:09:45 PM)

After market: 88.51 0 (0%)

88.51

-2.21 (-2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners91.32%
Inst Owner Change5.21%
Ins Owners1.45%
Ins Owner Change1.2%
Market Cap5.34B
Revenue(TTM)521.31M
Net Income(TTM)-23.36M
Analysts85.88
Price Target116.99 (32.18%)
Short Float %14.99%
Short Ratio9.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-100.62%
Min EPS beat(2)-331.01%
Max EPS beat(2)129.77%
EPS beat(4)3
Avg EPS beat(4)-31.65%
Min EPS beat(4)-331.01%
Max EPS beat(4)129.77%
EPS beat(8)4
Avg EPS beat(8)-26.24%
EPS beat(12)6
Avg EPS beat(12)-40.65%
EPS beat(16)10
Avg EPS beat(16)-27.1%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.25%
Max Revenue beat(2)2.97%
Revenue beat(4)4
Avg Revenue beat(4)7.55%
Min Revenue beat(4)0.25%
Max Revenue beat(4)15.82%
Revenue beat(8)7
Avg Revenue beat(8)4.66%
Revenue beat(12)11
Avg Revenue beat(12)7.3%
Revenue beat(16)14
Avg Revenue beat(16)9.25%
PT rev (1m)0%
PT rev (3m)12.12%
EPS NQ rev (1m)-15837.5%
EPS NQ rev (3m)-329.82%
EPS NY rev (1m)-720.95%
EPS NY rev (3m)-532.55%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)3.81%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)5.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.24
P/FCF 97.33
P/OCF 95.67
P/B 16.97
P/tB 99.33
EV/EBITDA 2457.55
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)0.91
FCFY1.03%
OCF(TTM)0.93
OCFY1.05%
SpS8.64
BVpS5.22
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.77%
ROE -7.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.77%
FCFM 10.53%
ROA(3y)-13.72%
ROA(5y)-21.62%
ROE(3y)-37.37%
ROE(5y)-55.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.28%
GM growth 5YN/A
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 5.65
Debt/EBITDA 146.96
Cap/Depr 3.93%
Cap/Sales 0.18%
Interest Coverage N/A
Cash Conversion 2648.34%
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2.55
Altman-Z 5.98
F-Score6
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)92.83%
Cap/Depr(5y)691.42%
Cap/Sales(3y)5.73%
Cap/Sales(5y)23.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.59%
EPS Next Y-105.78%
EPS Next 2Y52.72%
EPS Next 3Y66.03%
EPS Next 5Y81.09%
Revenue 1Y (TTM)54.74%
Revenue growth 3Y89.13%
Revenue growth 5YN/A
Sales Q2Q%49.81%
Revenue Next Year25.28%
Revenue Next 2Y23.51%
Revenue Next 3Y24.06%
Revenue Next 5Y25.19%
EBIT growth 1Y74.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-473.57%
EBIT Next 3Y20.74%
EBIT Next 5YN/A
FCF growth 1Y614.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y440.7%
OCF growth 3YN/A
OCF growth 5YN/A

MIRUM PHARMACEUTICALS INC / MIRM Fundamental Analysis FAQ

What is the fundamental rating for MIRM stock?

ChartMill assigns a fundamental rating of 4 / 10 to MIRM.


What is the valuation status for MIRM stock?

ChartMill assigns a valuation rating of 3 / 10 to MIRUM PHARMACEUTICALS INC (MIRM). This can be considered as Overvalued.


Can you provide the profitability details for MIRUM PHARMACEUTICALS INC?

MIRUM PHARMACEUTICALS INC (MIRM) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for MIRM stock?

The Earnings per Share (EPS) of MIRUM PHARMACEUTICALS INC (MIRM) is expected to decline by -105.78% in the next year.